Table 4.
Average changes in clinical indicators and serum biochemistries by EHD treatment group
| EHD (n=33) | Controls (n=20) | P value* | |
|---|---|---|---|
| Left ventricular mass (g) | −8.2 (−18.5, 2.1) | +13.6 (0.3, 27.0) | 0.01* |
| Albumin (g/L) | +0.55 (−0.84, 1.94) | −0.40 (−2.18, 1.38) | 0.40 |
| Amino acids | |||
| Valine (μmol/L) | +28.6 (10.2, 47.0) | −2.9 (−26.5, 20.8) | 0.04* |
| Isoleucine (μmol/L) | +24.2 (9.4, 39.0) | +0.1 (−19.0, 19.1) | 0.049* |
| Methionine (μmol/L) | +4.6 (−0.01, 9.3) | −2.0 (−7.9, 4.0) | 0.09 |
| Threonine (μmol/L) | +29.6 (−4.9, 64.2) | −26.7 (−71.1, 17.7) | 0.049* |
| Lysine (μmol/L) | −12.5 (−49.7, 24.6) | −26.1 (−73.8, 21.6) | 0.65 |
| Leucine (μmol/L) | +14.7 (2.6, 26.8) | +0.2 (−15.3, 15.7) | 0.15 |
| Histidine (μmol/L) | +8.2 (−2.5, 18.9) | +1.6 (−12.2, 15.3) | 0.45 |
| Phenylalanine (μmol/L) | +7.1 (−1.8, 15.9) | −4.5 (−15.8, 6.8) | 0.11 |
| Glutathione (μmol/L) | +0.103 (−0.014, 0.220) | −0.145 (−0.295, 0.005) | 0.01* |
| Average essential AAsa | +0.38 (0.08, 0.68) | −0.12 (−0.50, 0.27) | 0.047* |
| Average nonessential AAsa | +0.31 (0.04, 0.67) | −0.20 (−0.54, 0.14) | 0.02* |
AAs= amino acids; BP=blood pressure, EHD=in-center HD; HD=hemodialysis, table shows average 12-month change in values (95% confidence intervals)
a
To calculate average changes in essential and nonessential AA, absolute AA concentrations were normalized according to their z-scores, then the normalized concentrations of all baseline and 12 month essential and nonessential AAs were averaged for each subject, then the change between baseline and 12 month average AAs were calculated for each subject. Finally, the average change in average essential and nonessential AA were calculated by treatment group.
*
Significant at P<0.05